Capítulo 4.3. Debilidad muscular aguda

Bibliografía
 
1. Layzer RB. Neuromuscular manifestations of systemic diseases. Plum F, Baringer JR y Gilman S, ed. FA Davis Company. Philadelphia, 1985.
2. Ringel SP. Clinical presentations in neuromuscular disease. En : Vinken PJ and Bruyn GW. Handbook of Clinical Neurology. Elsevier North-Holland Biomedical Press, 1979; vol 40:295-348.
3. Cherington M. Acute muscular weakness. En: Vinken PJ, Bruyn GW, Klawans HL, Matthews WB. Handbook of Clinical Neurology. Elsevier Science Publishers, Amsterdam, 1987; vol 51:287-293.
4. Hughes RAC, Bihari D. Acute neuromuscular respiratory paralysis. J Neurol Neurosurg Psychiatry 1993; 56: 334-343.
5. Kimura J. Electrodiagnosis in diseases of nerve and muscle: Principles and practice. FA Davis Company, Philadelphia 1989.
6. So YT, Olney RK, AAEM case report 23: Acute paralytic poliomyelitis. Muscle Nerve 1991; 14: 1159-1164.
7. Albers JW, Kelly JJ Jr. Acquired inflammatory demyelinating polyneuropathies: Clinical and electrodiagnostic features. Muscle Nerve 1989; 12: 435-451.
8. Dowling PC, Blumberg BM, Cook SD. Guillain-Barré syndrome. En : Vinken PJ, Bruyn GW, Klawans HL, Mathews WB. Handbook of Clinical Neurology. Elsevier Science Publishers, Amsterdam 1987; vol 51: 239-262.
9.Illa I, Ortiz N, Gallardo E, Juarez C, Grau JM, Dalakas M. Acute axonal Guillain-Barré syndrome with Ig G antibodies against motor axons following parenteral injection of gangliosides. Ann Neurol 1995; 38: 218-224.
10.Ropper AH, Shahani BT. Diagnosis and management of acute areflexic paralysis with emphasis on Guillain-Barré syndrome. En: Asbury AK y Gilliat RW, ed. Peripheral nerve disorders. A practical approach. Butterworths, 1984;21-45.
11.Olney RK, Aminoff MJ. Electrodiagnosic features of the Guillain-Barré syndrome: the relative sensitivity of different techniques. Neurology 1990; 40: 471-475.
12.Albers JW, AAEE Case Report 4: Guillain-Barré syndrome. Muscle Nerve 1989; 12: 705-711.
13.Cornblath DR, Mellits ED, Griffin JW et al. Motor conduction studies in Guillain-Barré syndrome: description and prognostic value. Ann Neurol 1988; 23: 354-359.
14.Asbury AK, Cornblath DR. Assessment of current diagnostic criteria for Guillain-Barré syndrome. Ann Neurol 1990; 27(suppl):21-24.
15.McKhann GM. Guillain-Barré syndrome: clinical and therapeutic observations. Ann Neurol 1990; 27(suppl): 13-16.
16.Guillain-Barré study group. Plasmapheresis and acute Guillain-Barré syndrome. Neurology 1985; 35: 1096-1104.
17.Osterman PO, Lundemo G, Pirskanen R et al. Beneficial effects of plasma exchange in acute inflammatory polyradiculoneuropathy. Lancet 1984; 2: 1296-1299.
18.French Cooperative group of plasma exchange in Guillain-Barré syndrome: Efficiency of plasma exchange in Guillain-Barré syndrome: role of replacement fluids. Ann Neurol 1987; 22: 753-761.
19.Hughes RAC, Newsom-Davies JM, Perkin GD, Pierce JM. Controlled trial of prednisolone in acute polyneuropathy. Lancet 1978; 2: 750-753
20.Van der Meché FGA, Schmitz PIM, Dutch Guillain-Barré study group. A randomized trial comparing intravenous immune globuline and plasma exchange in Guillain-Barré syndrome. N Engl J Med 1992; 326: 1123-1129.
21.The Dutch Guillain-Barré Syndrome Study Group. Treatment of Guillain-Barré syndrome with high-dose immune globulins combined with methylprednisolone: a pilot study. Ann Neurol 1994; 35: 741-752.
22.Serrano C, Illa I. Terapia inmunomoduladora de enfermedades neurológicas con inmunoglobulinas endovenosas. Neurología 1996; 11 (supl 2): 66-74. 
23.Leijten FSS, De Weerd AW. Critical illness polyneuropathy. A review of the literature, definition and pathophysiology. Clin Neurol Neurosurg 1994; 96: 10-19.
24.Bolton CF, Young B, Zochodne DW. The neurological complications of sepsis. Ann Neurol 1993; 33: 94-100.
25.Witt NJ, Zochodne DW, Bolton CF, Grand-Maison F, Wells G, Young GB et al. Peripheral nerve function in sepsis and multiple organ failure. Chest 1991; 99: 176-184.
26.Leitjen FSS, Harinck de Weerd JE, Poortvliet DCJ, De Weerd AW. The role of polyneuropathy in motor convalescence after prolonged mechanical ventilation. JAMA 1995; 274: 1221-1225.
27.Zochodne DW, Bolton CF, Wells GA, Gilbert JJ, Hahn AF, Brown JF et al. Critical illness polyneuropathy: a complication of sepsis and multiple organ failure. Brain 1987; 110: 819-842.
28.Bolton CF. Neuromuscular complications of sepsis. Intensive Care Med 1993; 19: S58-S63.
29.Coakley JH, Nagendran K, Honavar M, Hinds CJ. Preliminary observations on the neuromuscular abnormalities in patients with organ failure and sepsis. Intensive Med Care 1993; 19: 323-328.
30.Hinds CJ, Yarwood GD, Coakley JH. Acquired neuromuscular abnormalities in intensive care patients. En: Vincent JL,ed. Yearbook of intensive care and emergency medicine. Springer-Verlag. New York 1994; 655-667.
31.Chad DA, Lacomis D. Critically ill patients with newly acquired weakness: the clinicopathological spectrum. Ann Neurol 1994; 35 (3): 257-258.
32.Op de Coul AAW, Lambregts PCLA, Koeman J, van Puyenbroek MJE, Ter Laak HJ, Gabreëls-Festen AAWM. Neuromuscular complications in patients given Pavulon (pancuronium bromide) during artificial ventilation. Clin Neurol Neurosurg 1985; 87: 17-22.
33.Le Quesne PM, McLeod JC. Peripheral neuropathy following a single exposure to arsenic. J Neurol Sci 1977; 32: 437-451. 36.
34.Donofrio PD, Wilbourn AJ, Albers JW, Rogers L, Salanga V, Greenberg HS. Acute arsenic intoxication presenting as Guillain-Barré-like syndrome. Muscle Nerve 1987;10: 114-120.
35.Oh SJ. Electrophysiological profile in arsenic neuropathy. J Neurol Neruosurg Psychiatry 1991; 54: 1103-1105.
36.Windebank AJ. Peripheral neuropathy due to chemical and industrial exposure. En : Vinken PJ, Bruyn GW, Klawans HL, Matthews WB, ed. Handbook of Clinical Neurology. Elsevier Science Publishers, Amsterdam 1987 ; vol 51: 63-292.
37. Wolff FA, Edelbrock PM. Neurotoxicity of arsenic and its compounds. Wolff FA ed. Handbook of Clinical Neurology. Intoxications of the nervous system.Part I. Elsevier Science BV. Amsterdam,1994.
38.Tschudy DP, Valsamis M, Maynussen CR. Acute intermittent porphyria: clinical and selected research aspects. Ann Inter Med 1975; 83: 851-864.
39.Ridley A. Porphyric neuropathy. En: Dyck PJ, Thomas PK, Lambert EH, Bunge R. Peripheral neuropathy. WB Saunders Co. Philadelphia ,1984 p1704-1716.
40.Tishler D, Knighton DJ, Schumaker HM. Screening test for intermittent acute porphyria. Lancet 1976;1: 303.
41.Albers JW, Robertson WC, Daube JR. Electrodiagnostic findings in acute porphyric neuropathy. Muscle Nerve 1978; 1:292-296.
42.Watson CJ, Pierach CA, Bossenmaier I, Cardinal R. Use of hematin in the acute attack of the "inducible" hepatic porphyria. Adv Intern Med 1978;23:265.
43.Goetsch CA, Bissell DM. Inestability of hematin used in the specific treatment of acute hepatic porphyria. N Engl J Med 1987; 315: 235-238.
44.Lamon JM et al. Hematin therapy for acute porphyria. Medicine 1979; 58: 252-269
45.Furlan AJ, Hanson M, Cooperman A et al. Acute areflexic paralysis. Association with hyperalimentation and hipophosphatemia. Arch Neurol 1975; 32: 706-707.
46.Weintraub MI. Hypophosphatemis mimicking acute Guillain-Barré-Strohl syndrome. A complication of parenteral hyperalimentation. JAMA 1976; 235: 1040-1041.
47.Baden DG, Fleming LE, Bean JA. Marine toxins. de Wolff FA ed. Handbook of clinical neurology. Intoxications of the Nervous System. Part II.. Elsevier Science BV, 1995; vol 21 (65):141-175. 
48.Rothrock JF, Johnson PC, Rothrock SM, Merkley R. Fulminant polyneuritis after overdose of disulfiram and alcohol. Neurology 1984; 34: 357-359.
49.Filley CM, Graff-Radford NR, Lacy JR et al. Neurological manifestations of podophyllin toxicity. Neurology 1982; 32: 308-311.
50.Vernay D, Dubost JJ, Thevent JP, Sauvezie B, Rampon S. "Choreé fibrillaire de Morvan" followed by Guillain-Barré syndrome in a patient receiving gold therapy. Arthritis Rheum 1986; 29: 1413-1414.
51.Brust JCM, Hammer JS, Challenor Y, Healton EB, Lesser R: Acute generalized polyneuropathy accompanying lithium poisoning. Ann Neurol 1979; 6: 360-2.
52.Cavanagh JB, Fuller NH, Johson HRM, Rudge P. The effects of thallium salts, with particular reference to the nervous system changes. Q J Med 1974; 43: 293-319.
53.Critchley EMR. Neuropathies due to drugs. En: Vinken PJ, Bruyn GW, Klawans HL, Matthews WB, ed. Handbook of Clinical Neurology. Elsevier Science Publishers, Amsterdam, 1987 vol 51, 293-314.
54.Shaumburg HH, Spencer PS. Human toxic neuropathy due to industrial agents. En: Dyck PJ, Thomas PK, Lambert EH, Bunge R ed. Peripheral neuropathy. WB Saunders Company 1984; 2115-2132. 
55.Bruyn GW, Yaqub BA. Neurotoxic effects of n-hexane and methyl-n-butyl ketone. Wolff FA, ed. Handbook of Clinical Neurology. Intoxicacions of the Nervous System part I..  Elsevier Science. 1994; vol 20 (64): 81-94.
56.Engel AG. Acquired autoimmune myasthenia gravis. En: Engel AG, Banker BQ ed. Myology. McGraw-Hill Book Company 1986;1925-1954.
57.Engel AG. Myasthenia Gravis and Myasthenic syndromes. Ann Neurol 1984; 16:519-534.
58.Drachman DB. Myasthenia Gravis (First of two parts). N Engl J Med 1978; 298: 136-141.
59.Drachman DB. Myasthenia Gravis (Second of two parts). N Engl J Med 1978; 298: 186-192.
60.Pradas J, Illa I. Factores de predicción de la respuesta al tratamiento de la miastenia gravis con prednisona. Neurología 1990; 5: 11-13.
61.Keesey JC, AAEE Minimonograph 33: Electrodiagnostic approach to deffects of neuromuscular transmission. Muscle Nerve 1989; 12: 613-626.
62.Lennon VA. Myasthenia gravis: diagnosis by assay of serum antibodies. Mayo Clin Proc 1982; 57: 723-724.
63.Simpson JA, Thomaides T. Treatment of Myasthenia Gravis: an audit. Quart J Med 1987; 244: 693-704.
64.Drachman DB. Present and future treatment in myasthenia gravis. N Engl J Med 1987; 316: 743-745.
65.Dau PC, Lindstrom JM, Cassel CK, Denys EH, Shev LE, Spitler LE. Plasmapheresis and immunosupressive drug therapy in myasthenia gravis. N Engl J Med 1977; 297: 1134-1140.
66.Gadjos PH, Outin H, Elkharat D, Brunel D, de Rohan-Chabot P, Raphael JC et al. High-dose intravenous gammaglobulin for myasthenia gravis. Lancet 1984; i: 406-407
67.Arsura EL., Bick A, Brunner NG, Grob D. Effects of repeated doses of intravenous immunoglobulin in myasthenia gravis. Am J Med Sci 1988; 295:438-443. 
68.Fateh-Moghadam A, Wiek M, Beisinger U, Geursen RG. High-dose of intravenous gammaglobulin for myasthenia gravis. Lancet 1984; 1: 848-849.
69.Case records of the Massachusets General Hospital. N Engl J Med 1980; 303: 1347-1355.
70.Cherington M. Botulism: Ten-year experience. Arch Neurol 1974; 30: 432-437.
71.Hughes JM, Blumenthal JR, Merson MH, Lombard GL, Dowell VR Jr, Gangarosa EJ. Clinical features of type A and B food-borne botulism. Ann Intern Med 1981; 95: 442-445.
72.Cherington M, Smith RH, Montecucco C. Microbial toxins. Wolff FA, ed. Handbook of clinical neurology. Intoxications of the Nervous System. Part II. Elsevier Science B.V. 1995, vol 21 (65): 209-215.
73.Barr CW, Claussen G, Thomas D, Fesenmeier JT, Pearlman RL, Oh SJ. Primary respiratory failure as the presenting symptom in Lambert-Eaton myasthenic syndrome. Muscle Nerve 1993; 16: 712-715.
74.Anderson TJ, Carroll GJ, Avery SF, Donaldson IM, Parkin PJ. Eaton-Lambert myasthenic syndrome: two cases with typical and atypical features. NZ J Med 1990; 103: 240-242.
75.O'Neill JH, Murry MMF, Newsom-Davis J. The Lambert-Eaton myasthenic syndrome. Brain 1988; 111: 577-596.
76.Jenny DB, Goris GB, et al. Hypermagnesemia following irrigation of renal pelvis: Cause of respiratory depression. JAMA 1978; 240: 1378.
77.Argov Z, Mastaglia FL. Disorders of neuromuscular transmission caused by drugs. N Eng J Med 1979; 301: 409-413.
78.Goetz CG, Klawans HL, Cohen MM. Neurotoxic agents. En: Baker AB and Joynt RJ, eds. Clinical Neurology. JB Lippincott Company, Philadelphia, Harper & Row Publishers,1988; vol 2:1-84.
79.Solé Violán J, Martínez Chuecos J, Molinero Somolinos F, Marco Moreno JM, Rubio Sanz R, Rodríguez Nieto I. Manifestaciones neurológicas en la intoxicación aguda por insecticidas organofosforados. Med Clin (Barcelona) 1985; 85: 217-220.
80.Senanayake N, Johnson MK. Acute polyneuropathy after poisoning by a new organophosphate insecticide. N Engl J Med 1982; 306: 155-157.
81.Senanayake N, Karalliedde L. Neurotoxic effects of organophosphorus insecticides: an intermediate syndrome. N Engl J Med 1987;316:761-763.
82.Davies JE. Changing profile of pesticide poisoning. N Engl J Med 1987;316: 807-808.
83.Whittaker M. Plasma cholinesterase variants and the anaesthetist. Anesthesia 1980; 35: 174-197.
84.Stovner J, Stadskleiv K. Suxamethonium apnea terminated with commercial serum cholinesterase. Acta Anaesth Scand 1976; 20: 211-215.
85.Viby-Mogensen J. Prolonged apnoea after suxamethonium: An analysis of the first 225 cases reported to the Danish cholinesterase research unit. Acta Anaesth Scand 1978; 22: 371-380.
86.MacFarlane IA, Rosenthal FD. Severe myopathy after status asthmaticus. Lancet 1977; 2: 615.
87.Sitwell LD, Weinshenker BG, Monpetit V, Reid D. Complete ophthalmoplegia as a complication of acute corticosteroid and pancuronium associated myopathy. Neurology 1991; 41: 921-922.
88.Ramsay DA, Zochodne DW, Robertson DM, Nag S, Ludwin SK. A syndrome of acute severe muscle necrosis in intensive care unit patients. J Neuropath Exp Neurol 1993; 52 (4): 387-398.
89.Zochodne DW, Ramsay DA, Saly V, Shelley S, Moffatt S. Acute necrotizing myopathy of intensive care: electrophysiological studies. Muscle Nerve 1994; 17: 285-292.
90.Al-Lozi MT, Pestronk A, Yee WC, Flaris N, Cooper J. Rapidly evolving myopathy with myosin-deficient muscle fibers. Ann Neurol 1994; 35: 273- 279.
91.Danon MJ, Carpenter S. Myopathy with thick filament (myosin) loss following prolonged paralysis with vecuronium  during steroid treatment. Muscle Nerve 1991; 14: 1131-1139.
92.Bachmann P, Gaussorgues Ph, Piperno D, Fussy A, Jaboulay JM, Robert D. Myopathie aiguë au décours de l´etat de mal asthmatique. Presse Méd 1987; 30: 1486.
93.Williams TJ, O´Hehir RE, Czarny D, Horne M, Bowes G. Acute myopathy in severe acute asthma  treated with intravenously administered corticosteroids. Am Rev Respir Dis 1988; 137: 460-463.
94.Bachmann P, Gaussorgues P, Piperno D, Jaboulay JM, Jean G, Boyer F, Robert D. Hydrocortisone and pancuronium bromide: acute myopathy during status asthmaticus. Critical Care Med 1988; 16 (7): 731-732.
95.Posner MR, Caudill MA, Brass R, Ellis E. Legionnaires´disease associated with rhabdomyolysis and myoglobinuria. Arch Inter Med 1980; 140: 848-850.
96.Gamboa ET, Eastwood AB, Hays AP, MaxwellJ, Penn S. Isolation of influenza virus from muscle in myoglobinuric polymyositis. Neurology 1979; 29: 1323-1335.
97.Congy F, Hauw JJ, Wang A, Moulias R. Influenzal acute myositis in the elderly. Neurology 1980; 30: 877-878.
98.Rouleau G, Karpati G, Carpenter S, Soza M, Prescott S, Holland P. Glucocorticoid excess induces preferential depletion of myosin in denervated skeletal muscle fibers. Muscle Nerve 1987; 10: 428-438.
99.Riggs JE. Periodic paralysis. Clinical Neuropharmacology. Raven Press Ltd, New York 1989; 12: 249-257.
100.Engel AG. Periodic paralysis . En: Engel AG y Bankeer BQ, eds. Myology. McGraw-Hill Book Company 1986; 1843-1870.